incidence of FN, complication rates and mortality
Despite relatively high rates of low neutrophil counts during standard dose chemotherapy regimens for malignancies other than acute leukemias, rates of FN, other complication rates and mortality rates are relatively low for most standard chemotherapies (Table 1) .
These rates do not justify the systematic use of hematopoietic growth factors (hGFs) such as granulocyte colony-stimulating factor (G-CSF) or its pegylated form (pegfilgrastim) in prophylaxis of chemotherapy-induced neutropenia unless the risk of FN exceeds 20%, or there are special circumstances as outlined below. Colony-stimulating growth factors should be avoided in patients who are not at high risk for FN or neutropenic complications. The use of hGFs for treatment of FN is also not recommended, except in settings with increased morbidity and mortality, including sepsis, tissue infection and prolonged neutropenia. These agents should be particularly avoided in patients with infections not related to neutropenia, such as community-or hospital-acquired pneumonia [I, A].
indication for primary prophylaxis of FN by hGFs Table 2 describes the indications for primary prophylaxis of FN  by hGFs and Table 3 gives examples of chemotherapy regimens with a risk of FN of 20%.
special situations for use of hGFs for standard therapy Table 4 describes special situations for the use of hGFs for standard therapy.
dose schedule, route of application of G-CSF and pegfilgrastim There is also a risk of worsening thrombocytopenia when hGFs are given immediately before or simultaneously with chemotherapy.
There is a possible risk of subsequent acute myeloid leukemia (AML) or myelodisplastic syndrome (MDS) in women receiving adjuvant chemotherapy for breast cancer and hGFs. However, this is confounded by the higher doses of chemotherapy received by patients receiving hGFs compared with those receiving standard dose reductions. Long-term follow-up of dose-dense adjuvant chemotherapy where total dose is the same has not demonstrated any difference in leukemic risk. If an increased risk is confirmed in some settings, the absolute risk is low (1.8% compared with 0.7% within 48 months of breast cancer diagnosis) and, therefore, the benefits of hGFs still outweigh the risk.
use of G-CSF and pegfilgrastim in highrisk situations
Therapy of acute leukemias, autologous and allogeneic stem cell transplantations (TPLs) lead to higher risks of FN and potentially lethal complications.
Incidence of FN in high-risk situations: regular during autologous and allogeneic peripheral blood stem-cell (PBSC) TPLs and bone marrow TPL, during graft failure, in 35-48% of AML cases at diagnosis and in 13-30% during acute lymphoblastic leukemia (ALL) induction chemotherapy.
Mortality: 0-10% in autologous TPL, highly variable in allogeneic TPL, 80% during graft failure, 20-26% during first 2 months in AML and 2-10% during induction of ALL.
indications for granulopoietic CSFs in high-risk situations special comments on CSFs as a treatment for radiation injury
The use of CSFs as treatment for radiation injury is shown in Table 6 . AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ANC, absolute neutrophil count; FN, febrile neutropenia; G-CSF, granulocyte colony-stimulating factor; hGF, hematopoietic growth factor; MDS, myelodisplastic syndrome; PBSC TPL, peripheral blood stem cell transplantation. 
